newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

  • Instil Bio, Inc. reported first quarter 2026 financial results & provided a corporate update on May 15, 2026.
  • The company is actively evaluating potential acquisitions & in-licensing opportunities to access novel therapeutic candidates.
  • Cash, cash equivalents, restricted cash, & marketable securities totaled approximately $74.7 million as of March 31, 2026.
  • The current cash position is expected to fund the operating plan beyond 2027.
  • Research & development expenses were $0.7 million for the quarter ended March 31, 2026, down from $5.4 million in the same period in 2025.
  • General & administrative expenses were $5.3 million for the quarter ended March 31, 2026, down from $9.1 million in the same period in 2025.
  • Restructuring & impairment charges were $1.0 million for the quarter ended March 31, 2026, down from $16.1 million in the same period in 2025.
  • Net loss per share was $0.62 for the quarter ended March 31, 2026, compared to $4.32 in the same period in 2025.
  • Non-GAAP net loss per share was $0.32 for the quarter ended March 31, 2026, compared to $1.32 in the same period in 2025.
  • CEO Bronson Crouch stated the company is refining its strategy & positioning for growth with a strong balance sheet.
  • The company noted there is no assurance that any acquisition or in-licensing transaction will occur.
  • Instil Bio is a biotechnology company focused on identifying & advancing innovative therapeutics.